Niacin in the long-term treatment of schizophrenia.
D000328:Adult; D001835:Body Weight; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005163:Factor Analysis, Statistical; D006801:Humans; D007642:Keratosis / Q000139:chemically induced; D007902:Length of Stay; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010859:Pigmentation Disorders / Q000139:chemically induced; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012649:Self Concept; D012917:Social Adjustment; D014149:Tranquilizing Agents / Q000627:therapeutic use
D009539:Nicotinic Acids; D014149:Tranquilizing Agents